Clinical trial
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
NCT04322682 · Montreal Heart Institute, Other · Terminated
Key facts
| NCT number | NCT04322682 |
|---|---|
| Title | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) |
| Official title | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) |
| Acronym | COVID-19 |
| Lead sponsor | Montreal Heart Institute, Other |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH Bill and Melinda Gates Foundation The Government of Quebec Dacima Software Inc. Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Corona Virus Infection |
| Intervention type | Drug |
| Interventions | Colchicine, Placebo oral tablet |
| Enrollment | 4,506 |
| Start date | Mar 23, 2020 |
| Primary completion | Jan 21, 2021 |
| Completion | Jan 21, 2021 |
| First posted | Mar 26, 2020 |
| Last update posted | Dec 13, 2024 |
| Countries | Brazil, Canada, Greece, South Africa, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: